Science & Tech Current Affairs
Science & Technology Current Affairs 2019-2020 category comprises current affairs with all important national / international updates in science and tech and events for the year 2019-2020 for UPSC, States, Civil services, SSC and other competitive examinations of India and States.
The move to leapfrog India’s space activities into the next stage by transforming the Indian Space Sector for the future challenges was made during a meeting of the Union Cabinet on 24th June 2020.
Under the Chairmanship of the Prime Minister of India Narendra Modi, to further advance India’s capabilities in the space sector, the Cabinet approved the participation of the private sector in various space activities.
This long-awaited move from the Indian Government is highly significant in order to establish India’s position as one of the important players in the global space economy.
The decision will bring new energy and dimension to the entire space sector, which in the long run will also help in building an AtmaNirbhar Bharat by making the space sector self-reliant and technologically advanced.
Role of IN-SPACe and NSIL
- The Cabinet has approved setting up of Indian National Space Promotion and Authorization Centre (IN-SPACe). Through friendly regulatory and encouraging policies, IN-SPACe will have the responsibility to guide the private sector in various space activities.
- State-owned enterprise New Space India Limited (NSIL) was founded in March 2019. The NSIL will have the responsibility to change the economic and social policies for encouraging the private sector in space activities by making Indian Space Sector demand-driven from the current supply-driven model.
Tags: Atmanirbhar Bharat • Indian National Space Promotion and Authorization Centre (IN-SPACe) • Narendra Modi • New Space India Limited (NSIL) • Union Cabinet Decisions
In its June 13th, 2020 guidelines for Clinical Management Protocol for COVID-19, the Union Health Ministry as a part of investigational therapy added ‘Remdesivir’ only for restricted emergency use. A week after, on 21st June 2020, Hetero and Cipla Pharmaceuticals were granted approval by the Drug Controller General of India for the production and marketing of the antiviral drug under its respective generic names.
The United States-based biopharmaceutical company, Gilead Sciences is the developer of the drug. In May 2020 Cipla was granted the voluntary non-exclusive by Gilead Science for manufacturing and marketing of the drug in India under generic drug name ‘CIPREMI’.
Japan was the first country to approve Remdesivir drug as a treatment for COVID-19. At present Remdesivir is only available in the injectable method. On 22nd June 2020, Gilead Sciences had announced had it will soon start Phase I trial for the inhaled version of Remdesivir.
In May 2020, clinical trials conducted under ACTT-1 (Adaptive COVID-19 Treatment Trial) with Remdesivir in more than 60 centers across the United States, Asia, and Europe had shown promising results when compared with the patients who were given placebo. During the trails a total of 1063 patients were given Remdesivir, the mortality rate was 7.1 %.